published meta-analysis   sensitivity analysis   studies

Comirnaty - first boost in COVID-19 prophylaxis (excluding children) - Summary of results

OutcomeTE95% CInkI2ROBPub. bias confirmed COVID (any severity)detailed resultsC4591031- first boost, 2021 0.05 [0.02; 0.13] 0.05[0.02; 0.13]C4591031- first boost, 202110%10,125NAnot evaluable severe COVID-19 (FDA definition)detailed resultsC4591031- first boost, 2021 0.25 [0.01; 5.50] 0.25[0.01; 5.50]C4591031- first boost, 202110%10,125NAnot evaluable severe COVID-19 occurrencedetailed resultsC4591031- first boost, 2021 0.25 [0.01; 5.50] 0.25[0.01; 5.50]C4591031- first boost, 202110%10,125NAnot evaluable arrhythmiadetailed resultsC4591031- first boost, 2021 1.99 [0.07; 59.22] 1.99[0.07; 59.22]C4591031- first boost, 202110%10,075NAnot evaluable hypertensiondetailed resultsC4591031- first boost, 2021 0.50 [0.02; 14.80] 0.50[0.02; 14.80]C4591031- first boost, 202110%10,075NAnot evaluable Myocardial infarction detailed resultsC4591031- first boost, 2021 0.74 [0.17; 3.33] 0.74[0.17; 3.33]C4591031- first boost, 202110%10,075NAnot evaluable pulmonary embolismdetailed resultsC4591031- first boost, 2021 0.17 [0.01; 3.30] 0.17[0.01; 3.30]C4591031- first boost, 202110%10,075NAnot evaluable stroke (non-specific, hemorrhagic, and ischemic)detailed resultsC4591031- first boost, 2021 0.99 [0.06; 15.88] 0.99[0.06; 15.88]C4591031- first boost, 202110%10,075NAnot evaluable cerebral venous sinus thrombosis (CVST)detailed resultsC4591031- first boost, 2021 0.50 [0.02; 14.80] 0.50[0.02; 14.80]C4591031- first boost, 202110%10,075NAnot evaluable appendicitisdetailed resultsC4591031- first boost, 2021 3.97 [0.18; 88.14] 3.97[0.18; 88.14]C4591031- first boost, 202110%10,075NAnot evaluable0.010.01.0relative treatment effectwww.metaEvidence.org2024-05-08 21:04 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 89 - treatments: 1330 - roots T: 290